close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

441.12 +4.55 (+1.04%)
Streaming Delayed Price Updated: 12:36 PM EDT, May 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
73 74 Next >
Friday's session: top gainers and losers in the S&P500 index ↗
Via Chartmill
News headline image
Gilead Sciences and the 2026 Biotech Resurgence: A Leader in the Great Rotation
As of February 13, 2026, the financial markets are witnessing a historic "Great Rotation," where institutional capital is flowing out of overextended technology valuations and into the defensive,... 
Via MarketMinute
Topics Artificial Intelligence ETFs Government
News headline image
VRTX Q4 Deep Dive: Diversification Beyond Cystic Fibrosis Sets Stage for Next Growth Phase
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported revenue ahead of Wall Street’s expectations in Q4 CY2025, with sales up 9.5% year on year to $3.19 billion. The company expects the full... 
Via StockStory
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Posts Mixed Q4 2025 Results, Provides 2026 Guidance ↗
Via Chartmill
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Presents a Compelling Growth and Breakout Opportunity ↗
Via Chartmill
Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) Presents a Compelling Value Case ↗
Via Chartmill
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Emerges as a Prime GARP Investment Candidate ↗
Via Chartmill
News headline image
Vertex (VRTX) Q4 2025 Earnings Call Transcript ↗
Vertex (VRTX) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Vertex Pharmaceuticals’s (NASDAQ:VRTX) Q4 CY2025: Beats On Revenue
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) reported Q4 CY2025 results topping the market’s revenue expectations, with sales up 9.5% year on year to $3.19 billion. The company expects the full... 
Via StockStory
News headline image
Vertex Reports Fourth Quarter and Full Year 2025 Financial Results
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex Pharmaceuticals (VRTX) Q4 Earnings: What To Expect
Via StockStory
Topics Artificial Intelligence World Trade
News headline image
1 Reason I'd Buy Vertex Pharmaceuticals Stock and Never Sell ↗
Vertex stock has climbed more than 60% over three years. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Should You Buy Vertex Before Feb. 12? ↗
Biotech Vertex, known for its cystic fibrosis therapies, is set to report earnings on Feb. 12 
Via The Motley Fool
Topics Intellectual Property
News headline image
Provident Dumps 490,000 MapleBear Shares Worth $18 Million ↗
Maplebear Inc. connects North American households with personal shoppers through its technology-driven grocery delivery platform. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Should You Buy Vertex Pharmaceuticals Before Feb. 12? ↗
The next 12 months will be important for the drugmaker. 
Via The Motley Fool
News headline image
The Bond Market Is Flashing a Clear Warning About the Fed: 3 Stocks to Buy ↗
The bond market is speaking more loudly than the stock market about the likely direction of the Federal Reserve. 
Via The Motley Fool
Topics Bonds Economy Government
News headline image
2 Top Healthcare Stocks to Buy in February ↗
There's a bright future ahead for both, but it's important to be patient. 
Via The Motley Fool
Topics World Trade
News headline image
The Great Pipeline Grab: Life Sciences Deal Volume Skyrockets 82% as Big Pharma Battles the Patent Cliff
The life sciences sector has entered 2026 in the midst of a historic transformation, as deal volume and value surged by a staggering 82% over the past year. This "Great Rebound," fueled by a... 
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
News headline image
3 Market-Beating Stocks Worth Investigating
Companies that consistently increase their sales, margins, or returns on capital are usually rewarded with the best returns, and those that can do all three for years on end are almost always the... 
Via StockStory
News headline image
Prediction: 2026 Will Be the Year of Vertex Pharmaceuticals ↗
The biotech could be on the verge of expanding its lineup and entering a new era of growth. 
Via The Motley Fool
News headline image
1 Healthcare Stock to Consider Right Now and 2 We Brush Off
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have not only realized strong financial performance but... 
Via StockStory
Topics Stocks
News headline image
Breaking Barriers: How 2026’s Top Clinical Leaders Are Disrupting Chronic Disease Markets
Issued on behalf of Avant Technologies Inc. 
From Equity Insider
Via GlobeNewswire
News headline image
Reflecting On Therapeutics Stocks’ Q3 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX)
As the Q3 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including Vertex Pharmaceuticals (NASDAQ:VRTX) and its... 
Via StockStory
Topics Artificial Intelligence
News headline image
Vertex to Announce Fourth Quarter and Full Year 2025 Financial Results on February 12th
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Unpacking Q3 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) In The Context Of Other Therapeutics Stocks
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Vertex Pharmaceuticals... 
Via StockStory
Topics Artificial Intelligence
News headline image
My Forever Portfolio: 5 Stocks I Don't Plan on Ever Selling ↗
These stocks are definitely keepers. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
3 Profitable Stocks with Open Questions
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential. 
Via StockStory
News headline image
Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030 ↗
Plenty of growth lies ahead for these top healthcare companies. 
Via The Motley Fool
News headline image
Travere Therapeutics Shares Fall After FDA Extends Filspari Review for FSGS
On January 13, 2026, Travere Therapeutics (NASDAQ: TVTX) faced a sharp reversal of fortune as the U.S. Food and Drug Administration (FDA) announced a three-month extension for its review of Filspari... 
Via MarketMinute
News headline image
Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
From Vertex Pharmaceuticals Incorporated
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
73 74 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today